Oric Pharmaceuticals, Inc.
Close on Oct 19, 2026
- Market cap
- $1.37B
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 12, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 3, 2026 | After market close | – | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 4, 2026 | After market close | – | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 23, 2026 | After market close | – | $-0.30 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 13, 2025 | After market close | – | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 12, 2025 | After market close | – | $-0.47 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 5, 2025 | After market close | – | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 18, 2025 | After market close | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 12, 2024 | After market close | – | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 12, 2024 | After market close | – | $-0.45 | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 6, 2024 | After market close | – | $-0.37 | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 11, 2024 | After market close | – | $-0.49 | – |
Press releases
Announcements Oric Pharmaceuticals filed with the SEC
ORIC ® Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Updates
Results of operations · EX-99.1 to Form 8-K
ORIC ® Pharmaceuticals Reports First Quarter 2026 Financial Results and Operational Updates
Results of operations · EX-99.1 to Form 8-K
Forward-Looking Statements This presentation contains forward-looking
Other events · EX-99.1 to Form 8-K
ORIC ® Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Updates
Results of operations · EX-99.1 to Form 8-K
ORIC-944 Dose Exploration Data Update
Regulation FD disclosure · EX-99.1 to Form 8-K
ORIC ® Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Clinical and Operational Updates
Results of operations · EX-99.1 to Form 8-K
ORIC ® Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Updates
Results of operations · Exit or restructuring costs · EX-99.1 to Form 8-K
ORIC ® Pharmaceuticals Announces $125 Million
Material agreement · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
ORIC ® Pharmaceuticals Announces Potentially Best-In-Class Preliminary Efficacy and Safety Data from Ongoing Phase 1b Trial of ORIC-944 in Combination with AR Inhibitors for
Material agreement · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
ORIC ® Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Updates
Results of operations · EX-99.1 to Form 8-K
ORIC ® Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Updates
Results of operations · EX-99.1 to Form 8-K
ORIC ® Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operational Updates
Results of operations · EX-99.1 to Form 8-K
ORIC Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operational Updates
Results of operations · EX-99.1 to Form 8-K
ORIC Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Updates
Results of operations · EX-99.1 to Form 8-K
ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Updates
Results of operations · EX-99.1 to Form 8-K
ORIC Pharmaceuticals Announces $125 Million Private Placement Financing
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
statements that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this presentation, including statements regarding ORIC Pharmaceuticals, Inc.’s (“ORIC”,
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Initial Phase 1 Dose Escalation Data for ORIC-533 in Relapsed/Refractory Multiple Myeloma
Other events · EX-99.1 to Form 8-K
ORIC Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operational Updates
Results of operations · EX-99.1 to Form 8-K
Initial Phase 1 Dose Escalation Data of ORIC-114 in Patients with EGFR and
Other events · EX-99.1 to Form 8-K
ORIC Pharmaceuticals Reports Second Quarter 2023 Financial Results and Operational Updates
Results of operations · EX-99.1 to Form 8-K
ORIC Pharmaceuticals Announces $85 Million Private Placement Financing
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
ORIC Pharmaceuticals Reports First Quarter 2023 Financial Results and Operational Updates
Results of operations · EX-99 to Form 8-K
ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Updates
Results of operations · EX-99 to Form 8-K
ORIC Pharmaceuticals Provides Corporate Update and Highlights Key Upcoming Milestones
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
ORIC Pharmaceuticals Announces Clinical Development Collaboration with Pfizer for ORIC-533 in
Other events · EX-99.1 to Form 8-K
This Securities Purchase Agreement (this “ Agreement ”) is dated as of December 21, 2022, between ORIC Pharmaceuticals, Inc., a
Other events · EX-99.2 to Form 8-K
ORIC Pharmaceuticals Reports Third Quarter 2022
Results of operations · EX-99.1 to Form 8-K
ORIC Pharmaceuticals Reports Second Quarter 2022
Results of operations · EX-99.1 to Form 8-K
ORIC Pharmaceuticals Reports First Quarter 2022
Results of operations · EX-99.1 to Form 8-K
Fourth Quarter and Full Year 2021
Regulation FD disclosure · EX-99.1 to Form 8-K
ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2021
Results of operations · EX-99.1 to Form 8-K
ORIC Pharmaceuticals Provides Corporate Update and Highlights Key Upcoming Milestones
Results of operations · Other events · EX-99.1 to Form 8-K
ORIC Pharmaceuticals Reports Third Quarter 2021 Financial Results and Operational Update
Results of operations · EX-99.1 to Form 8-K
ORIC Pharmaceuticals Presents Initial Clinical Data from
Other events · EX-99.1 to Form 8-K